Litcius/Paper detail

1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C

M.D. Galsky, Vadim S. Koshkin, Matthew T. Campbell, Alexandra Drakaki, I. Alex Bowman, April A. N. Rose, Jason R. Brown, Jeanny B. Aragon‐Ching, Suresh Gadde, Amir Harandi, Jacob Rosenberg, Nobuaki Matsubara, Kevin M. Sokolowski, Mari Ichimaru, S. Chan, Sonia Franco, Thomas Powles

2024Annals of Oncology25 citationsDOI

Topics & Concepts

MedicinePembrolizumabMetastatic Urothelial CarcinomaOncologyInternal medicineCohortUrothelial carcinomaExpanded accessSafety profileAdverse effectImmunotherapyCancerBladder cancerBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersCancer Research and Treatments
1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C | Litcius